<DOC>
	<DOCNO>NCT00544349</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , leucovorin , fluorouracil , oxaliplatin , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , cetuximab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Giving one drug ( combination chemotherapy ) give together cetuximab may kill tumor cell . PURPOSE : This phase II trial study well give leucovorin together fluorouracil , cetuximab , oxaliplatin work treat patient stage IV colorectal cancer liver metastases remove surgery .</brief_summary>
	<brief_title>Leucovorin , Fluorouracil , Cetuximab , Oxaliplatin Treating Patients With Stage IV Colorectal Cancer Liver Metastases That Can Be Removed Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine efficacy regimen measurement objective response rate ( RECIST criterion ) . Secondary - Determine toxicity regimen . - Evaluate duration tumor response . - Determine duration rate tumor control . - Determine rate secondary resectability hepatic metastasis . - Evaluate progression-free survival - Determine rate progression tumor . - Determine overall survival . OUTLINE : This multicenter study . Patients receive cetuximab IV 1 hour , leucovorin calcium IV 2 hour , fluorouracil IV continuously 46 hour . Patients also receive oxaliplatin hepatic arterial infusion 2 hour . Treatment continue least 3 month absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary cancer colon rectum Isolated hepatic metastasis Not amenable curative resection requirement complex large ( i.e. , &gt; 4 liver segment ) liver resection Measurable disease ( RECIST criterion ) Original tumor must ( ) remove PATIENT CHARACTERISTICS : Inclusion criterion : WHO performance status 01 Life expectancy &gt; 3 month ANC ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 9 g/dL Creatinine ≤ 1.5 time normal Bilirubin ≤ 1.5 time upper limit normal Transaminases ≤ 5 time normal Not pregnant nursing Fertile patient must use effective contraception Exclusion criterion : Contraindication allergy grade 34 component study drug Peripheral neuropathy Intestinal occlusion subocclusion prior inflammatory intestinal disease Severe cardiac disease include follow : Symptomatic coronary disease Myocardial infarction past 6 month New York Heart Association grade IIIV cardiac insufficiency Severe arrhythmia ( even treat ) Active uncontrolled infection Other concurrent serious disorder Severe uncontrolled medical condition Other malignancy within past 5 year concurrently except basal cell skin cancer carcinoma situ cervix Study impossible due psychological , geographical , social reason Prisoners patient guardianship PRIOR CONCURRENT THERAPY : Exclusion criterion : Prior chemotherapy except adjuvant chemotherapy comprise fluorouracil , leucovorin calcium , capecitabine , oxaliplatin , irinotecan hydrochloride , and/or bevacizumab ( complete &gt; 6 month ago oxaliplatin irinotecanbased ) Prior epidermal growth factor ( EGF ) , monoclonal antibody inhibit transduction EGF receptor ( EGFR ) , treatment target EGFR Other concurrent anticancer immunotherapy , chemotherapy , hormone therapy Participation another study past 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>liver metastasis</keyword>
</DOC>